New Parkinson's drug HER-096 passes first safety check in small trial
Disease control
Completed
This early-stage trial tested the safety of a new drug called HER-096 for Parkinson's disease. It involved 32 people: healthy volunteers who got a single dose, and Parkinson's patients who received multiple doses over four weeks. The main goal was to check for side effects and ho…
Phase: PHASE1 • Sponsor: Herantis Pharma Plc. • Aim: Disease control
Last updated Jun 26, 2026 16:31 UTC